고혈당 치료 시장 : 시장 규모, 점유율 및 성장 분석 - 치료법별, 적응증별, 투여 경로별, 최종 사용자별, 환자 유형별, 유통 채널별, 지역별 업계 예측(2026-2033년)

Global Hyperglycemia Treatment Market size was valued at USD 58.4 Billion in 2024 and is poised to grow from USD 62.79 Billion in 2025 to USD 112.07 Billion by 2033, growing at a CAGR of 7.51% during the forecast period (2026-2033).

The global hyperglycemia treatment sector encompasses pharmaceuticals, biologics, and digital technologies aimed at managing blood glucose levels in individuals with diabetes. With the alarming rise in type-2 diabetes prevalence, which is anticipated to impact millions worldwide, the demand for innovative and safer glucose-lowering therapies is on the rise. The market has evolved from traditional human insulin to advanced solutions such as long-acting insulin analogs, oral incretin mimetics, and SGLT2 inhibitors, enhancing patient adherence while minimizing the risk of hypoglycemia. The advent of continuous glucose monitoring (CGM) devices has propelled the adoption of dose-adjusted insulin pumps and predictive algorithms, significantly reducing hospitalizations due to severe hyperglycemia. This convergence of technology and pharmacotherapy presents expansive market opportunities, encouraging investments in comprehensive solutions that integrate glucose management and medication delivery.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hyperglycemia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hyperglycemia Treatment Market Segments Analysis

Global hyperglycemia treatment market is segmented by treatment type, indication, route of administration, end user, patient type, distribution channel and region. Based on treatment type, the market is segmented into Drug Therapy and Non-Drug Management. Based on indication, the market is segmented into Type 1 Diabetes-Associated Hyperglycemia, Type 2 Diabetes-Associated Hyperglycemia, Stress-Induced Hyperglycemia, Gestational Hyperglycemia and Others. Based on route of administration, the market is segmented into Oral and Injectable. Based on end user, the market is segmented into Hospitals, Specialty Diabetes Clinics, Homecare Settings, Ambulatory Care Centers and Others. Based on patient type, the market is segmented into Pediatric, Adult and Geriatric. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hyperglycemia Treatment Market

The growing adoption of personalized therapies in the Global Hyperglycemia Treatment market is significantly influenced by advancements in genetic profiling and biomarker identification. These developments empower healthcare professionals to tailor treatments that specifically address distinct metabolic pathways, which enhances treatment effectiveness while minimizing potential side effects. As providers experience improved patient outcomes, their trust in these individualized approaches strengthens, leading to increased prescription rates of innovative medications over traditional alternatives. This heightened confidence motivates manufacturers to invest more in research and development to broaden their targeted product offerings, consequently driving a continuous cycle of innovation and fostering substantial market growth on a global scale.

Restraints in the Global Hyperglycemia Treatment Market

The complexity of obtaining regulatory approvals significantly hinders the progress of new hyperglycemia treatments, as approval agencies demand robust clinical evidence to establish safety and efficacy. This rigorous evaluation process often elongates development timelines, leading to increased uncertainty for both manufacturers and investors. As a result, companies may opt to prioritize more conventional products with clearer regulatory pathways, which can impede the introduction of innovative treatments. Furthermore, the divergent regulatory requirements across different regions necessitate customized submission strategies, draining resources and restricting the swift global market entry of newly developed solutions in the hyperglycemia treatment landscape.

Market Trends of the Global Hyperglycemia Treatment Market

The Global Hyperglycemia Treatment market is witnessing a notable trend towards the integration of precision nutrition into therapeutic strategies. Manufacturers are increasingly incorporating personalized dietary guidance based on genetic profiling and continuous glucose monitoring data, supported by AI-driven nutrition platforms. This holistic approach transcends traditional drug-only regimens, equipping patients with tailored meal plans that enhance glycemic control and improve adherence to treatment. By collaborating with nutrition technology firms, pharmaceutical companies position themselves as comprehensive partners in long-term metabolic health, fostering stronger patient-provider relationships through actionable, data-driven insights that consider lifestyle factors alongside pharmacological interventions.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Hyperglycemia Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Drug Therapy
  • Insulin
  • GLP-1 Receptor Agonists
  • SGLT2 Inhibitors
  • DPP-4 Inhibitors
  • Others
• Non-Drug Management

Global Hyperglycemia Treatment Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Type 1 Diabetes-Associated Hyperglycemia
• Type 2 Diabetes-Associated Hyperglycemia
• Stress-Induced Hyperglycemia
• Gestational Hyperglycemia
• Others

Global Hyperglycemia Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Hyperglycemia Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Diabetes Clinics
• Homecare Settings
• Ambulatory Care Centers
• Others

Global Hyperglycemia Treatment Market Size by Patient Type & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Hyperglycemia Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Hyperglycemia Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Indication, Route of Administration, End User, Patient Type, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Indication, Route of Administration, End User, Patient Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Indication, Route of Administration, End User, Patient Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Indication, Route of Administration, End User, Patient Type, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Indication, Route of Administration, End User, Patient Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mankind Pharma Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lexicon Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MannKind Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations